Artelo Biosciences Embarks on Restructuring Effort with Stock Split Move

Artelo Biosciences, a biotechnology company focused on developing novel treatments for cancer and other life-threatening diseases, has announced a 3-for-1 reverse stock split. The move aims to increase the market capitalization of the company, making it more attractive to investors. The 3-for-1 reverse stock split will reduce the number of outstanding shares from approximately 140 million to around 46 million. This adjustment is intended to enhance the company’s financial position and potentially pave the way for future growth initiatives. As part of its restructuring efforts, Artelo Biosciences has also implemented cost-saving measures, including staff reductions and adjustments to its research and development operations. The company is confident that these actions will help it navigate current market challenges and position itself for long-term success. The 3-for-1 reverse stock split is expected to take effect on [date], pending regulatory approval. Artelo Biosciences will provide further guidance on the implications of this move as more information becomes available.